GlassScriptPhysician profile
Bettina Pardo Harner
NPI 1043268857
$13,524.94
in general payments reported to CMS, 2019-2025
46 companies · $4,287 in 2025
The $4,287 reported for 2025 was more than what 79% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,094 · 2020: $539 · 2021: $884 · 2022: $1,445 · 2023: $876 · 2024: $2,400 · 2025: $4,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,268 · Travel and Lodging: $1,749 · Education: $397 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,267.64 |
| Travel and Lodging | $1,748.52 |
| Education | $396.63 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $4,582.74 | 2019-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $1,329.98 | 2019-2025 | Fintepla, Rystiggo, Briviact |
| Abbvie INC. | $968.91 | 2021-2025 | |
| Biogen, INC. | $745.54 | 2019-2025 | Tysabri, Vumerity |
| Teva Pharmaceuticals USA, INC. | $711.60 | 2019-2025 | Austedo Xr, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $456.33 | 2019-2024 | Ultomiris, Soliris |
| Lilly USA, LLC | $440.37 | 2019-2025 | Kisunla, Amyvid, Reyvow |
| Eisai INC. | $352.59 | 2023-2025 | |
| Allergan, INC. | $342.78 | 2019-2020 | |
| Genentech USA, INC. | $277.94 | 2023-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Novartis Pharmaceuticals Corporation | $254.84 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $225.33 | 2023-2025 | Rexulti |
| Sk Life Science, INC. | $214.89 | 2023-2024 | Xcopri |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $174.57 | 2025 | Rexulti |
| Emd Serono, INC. | $171.42 | 2019 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bettina Harner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.